RE: Roche13 Mar 2020 09:52
Re reading the RNS some interesting statements.
. In the past two weeks, the number of countries the Company is selling its COVID-19 test into has doubled to over 50, which is expected to increase further as the virus continues to spread. Currently, the Company is seeing significant sales from Europe and from a number of new and existing distribution partners across the Middle East.
However, it is clear that the demand for, and interest in, the Company's tests remains very high and the Directors' key focus is on ensuring Primerdesign can service the demand from as many customers as possible.
During the past two weeks, Primerdesign has scaled up its manufacturing capacity for the COVID-19 test and is currently meeting demand. The Company has purchased enough raw materials to manufacture 3.5 million COVID-19 tests. In addition, the Company has significantly increased its manufacturing capacity by appointing a third-party manufacturer, which specialises in high quality, GMP pharma and molecular diagnostic outsourcing and is based in mainland Europe. It is expected that the combination of the two manufacturing operations will support production of up to 2 million COVID-19 tests per month, which increases capacity by a factor of 10. This increase in output will be available within the next two weeks. The purchase of further raw materials and a further scale up of manufacturing capacity is possible under this outsourcing agreement.
The Company is working closely with the US Food and Drug Administration (FDA) to meet the stringent requirements for Emergency Use Approval (EUA) of its COVID-19 test and is hopeful its application will be successful.
The Company therefore expects to see an increase in the number of NHS hospitals purchasing Primerdesign's COVID-19 test.
Primerdesign continually reviews all publicly available COVID-19 genome databases to ensure its test remains effective in identifying all known strains of the COVID-19 virus. Consequently, the Company remains confident in the continued performance of its COVID-19 test as the virus continues to spread
Sign In
Follow the stocks
